Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Immune Modulation, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACKR2 drug discovery. Cell-based assays preserve the complex 7-transmembrane conformation of this atypical chemokine receptor. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | ACKR2 Lentivirus Premade Particles (Full-length 7-TM receptor for stable cell line construction. HEK293T packaging. Titers >1×10⁸ TU/mL) and Promise-ORF Cloning Vector (Codon-optimized, Sequence Verified) | View ACKR2 Products |
| Stable Cell Line Support | ACKR2 Promise-ORF Cloning Vector for lentiviral transduction. Native glycosylation pattern preservation. | View ACKR2 Products |
| Benchmark Ab | Anti-ACKR2 Monoclonal Antibody (recombinant positive control for flow cytometry. High purity >95%, Endotoxin Controlled) | View ACKR2 Products |
| Validator | ACKR2 siRNA Set (3 unique targets for knockdown verification and specificity controls. Sequence Verified) | View ACKR2 Products |
| Antigen (Fragment) | ACKR2 Extracellular Loop Peptide / Fc Fusion (high purity >95%, Endotoxin <1 EU/µg, HEK293 Expressed) | View ACKR2 Products |
| Related Target: ACKR3 | ACKR3 (CXCR7). Atypical chemokine receptor subfamily member. Critical for selectivity screening. | View ACKR3 Products |
| Related Target: CCR2 | CCR2. Primary chemokine receptor scavenged by ACKR2. Pathway counter-screening essential. | View CCR2 Products |
| Related Target: CCL2 | CCL2 (MCP-1). Key ligand for ACKR2 scavenging assays. High purity (>95%). | View CCL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native 7-TM Conformation & Glycosylation | HEK293 Expressed Lentivirus. Preserves post-translational modifications required for chemokine binding affinity. |
| Constitutive Internalization Dynamics | Stable Cell Line Generation supported. High-titer lentivirus enables flow cytometry-based internalization assays. |
| Cross-species Preclinical Evaluation (Cyno/Mouse) | Human/Mouse/Cyno ortholog ORF clones available with Sequence Verified identity. |
| ACKR Subfamily Selectivity & Homolog Off-target Toxicity (CCR2, CCR5) | ACKR1, ACKR3, ACKR4 homolog panels strictly verified by mass spec for counter-screening. Strictly Sequence Verified constructs ensure precise epitope presentation. |
| Lack of Reliable Assay Controls | Clinical Benchmark Antibodies (Biosimilars) and Validated siRNA included for specificity checks. Recombinant Benchmark Antibodies (high purity >95%) standardize assay windows. |
| False Positives in Ligand Scavenging Assays | Endotoxin Controlled reagents (<1 EU/µg) prevent LPS-mediated inflammatory assay artifacts. Validated siRNA included for rigorous target-specificity checks. |
Live ACKR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACKR2 (formerly D6) therapeutics is transitioning from basic academic exploration to early-stage translational development. As an atypical chemokine receptor, ACKR2 does not trigger classic G-protein signaling but acts as a critical scavenger receptor, internalizing and degrading inflammatory CC chemokines (e.g., CCL2, CCL3, CCL5). Major R&D players are evaluating ACKR2 modulation (both agonizing to resolve inflammation and antagonizing to alter the tumor microenvironment) as a novel approach for fibrotic diseases, autoimmune disorders (IBD, rheumatoid arthritis), and solid tumors resistant to current immunotherapies. As first-generation therapies targeting inflammatory resolution reach preclinical milestones, the next wave of R&D targets context-dependent chemokine gradients, combination strategies with checkpoint inhibitors, and selective tissue-specific modulation of chemokine clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Scavenger Modulators) | Biotech focus on inflammatory resolution / Extracellular Loop Targeting | IBD, Rheumatoid Arthritis, Autoimmune / Fibrosis | Internalization Assay (Need stable ACKR2+ cell lines via Lentivirus). Flow Cytometry Binding (Sequence Verified Stable Cell Lines). |
| Small Molecule Modulators (Allosteric) | Academic and early-stage biotech | Multiple Sclerosis, Psoriasis, Solid Tumors (TME modulation) | Selectivity Assay (Need ACKR vs CCR mutant panels). Receptor Internalization Assay (Native Conformation on HEK293/CHO). |
| Peptide Therapeutics (Ligand Mimetics) | Emerging platforms | Inflammatory Bowel Disease | Beta-arrestin Recruitment Assays (Need accurate full-length ORF delivery). |
| Bispecific (ACKR2 x Cytokine) | Emerging platforms | Cancer Immunotherapy | Cross-reactivity Validation (Need Human/Mouse ortholog proteins). |
| Cell Therapy (Engineered Tregs) | Cell therapy companies | Autoimmune Diseases | Expression Verification (Need anti-ACKR2 benchmark antibodies for flow cytometry). |